This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vanda Pharmaceuticals To Present At SLEEP 2012 26th Annual Meeting Of The Associated Professional Sleep Societies

WASHINGTON, June 4, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that the Company will present five posters during the scientific session at SLEEP 2012 on Monday, June 11.  The data presented on the posters are from Vanda's ongoing Phase III program for tasimelteon, a circadian regulator being evaluated to treat totally blind individuals with Non-24-Hour Disorder.

The following posters will be presented on Monday, June 11, beginning at 5:00 p.m. in the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. 

1.  Title: Timing and Duration of Nap Episodes are Coincident with Melatonin Acrophase       Authors: Schreffler ER, Licamele L, Dressman MA, Feeney J, Polymeropoulos MH

2.   Title: Significant Sleep Impairment in Totally Blind Individuals with N24HSWD      Authors: Torres R, Licamele L, Feeney J, Dressman MA, Polymeropoulos MH

3.  Title: Seventy Percent of Totally Blind People with Sleep Complaints Are Not Entrained to      the 24 Hour Clock      Authors: Dressman MA, Licamele L, Feeney J, Polymeropoulos MH

4.  Title: Pleiomorphic Expression of N24HSWD in the Totally Blind      Authors: Licamele L, Dressman M, Feeney J, Polymeropoulos MH

5.  Title: A National Registry of Totally Blind Individuals With Sleep-Wake Complaints      Authors: Gallagher A, Lavedan C

The posters will be archived for 30 days on Vanda's website at www.vandapharma.com

About Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact: Cristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (202) 734-3414 cristina.murphy@vandapharma.com

SOURCE Vanda Pharmaceuticals Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs